Referencias
- Mohindroo C, Ramirez RA. Management of peptide receptor radionuclide therapy toxicities in neuroendocrine neoplasm patients. Curr Treat Options Oncol 2026; 27:6.
- Sozio SJ, Raynor W, Becker MC, et al. Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: an overview of pathophysiology, risk factors, recognition, and treatment. EJNMMI Rep. 2024;8:29.
- Kuhnly N, Coviello JS, Kobza CA, et al. Carcinoid heart disease. J Adv Pract Oncol 2024;15:378-86.
- Maxwell JE, Naraev B, Halperin DM, et al. Shifting paradigms in the pathophysiology and treatment of carcinoid crisis. Ann Surg Oncol 2022;29:3072-84.
- Bardasi C, Benatti S, Luppi G, et al. Carcinoid crisis: A misunderstood and unrecognized oncological emergency. Cancers (Basel) 2022;14:662.
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). CIMA: Ficha técnica Lutathera 370 MBq/ml solución para perfusión [Internet]. Madrid: AEMPS; 2018 [citado 5 Feb 2026]. Disponible en: https://cima.aemps.es/cima/dochtml/ft/1171226001/P_1171226001.html
- Hack M, Bhamidipati CM. Management of carcinoid heart disease. Curr Probl Cancer 2024;52:101128.
- Pérez-Iruela JA, Pastor-Fructuoso P, De Gracia-Rodríguez C, et al. Adverse reactions to radiopharmaceuticals. Farm Hosp 2021;45:142-9.
